Based in New York, Silver will work in the Firm’s Advisory business and will focus on clients in the healthcare sector.
Silver has approximately 20 years of investment banking and corporate legal experience. He was most recently a Managing Director in Morgan Stanley’s Healthcare Investment Banking Group, where he advised a broad range of biopharmaceutical and pharmaceutical services clients on mergers and acquisitions, initial public offerings, the equity and debt capital markets, and royalty financing.
During his tenure at Morgan Stanley, Silver advised on a number of significant transactions, including Mylan Inc.’s $1.6 billion acquisition of Agila Specialties Private Limited; Quintiles Transnational Holdings, Inc.’s $1.1 billion initial public offering; The Carlyle Group and Hellman & Friedman’s $3.9 billion acquisition of Pharmaceutical Product Development, Inc.; three landmark financings totaling $320 million for Synageva Biopharma Corp.; and New York University’s sale of its worldwide royalty interest in Remicade to Royalty Pharma for $650 million.
Silver joins a global team of six healthcare sector advisory professionals led by Partners Christopher O’Connor and Philippe McAuliffe in New York, and Managing Director Nick Johnston in London.
Peter Weinberg, a Founding Partner and Head of Advisory at Perella Weinberg Partners, said, 'Attracting high-caliber talent in areas where we believe we can have meaningful impact and where we can provide world-class advice is a primary focus for the Firm. Adding Brian to our team illustrates this continued approach and enhances our coverage of the healthcare sector. His broad pharmaceutical and healthcare industry experience complements our existing capabilities and allows us to advise clients across a greater segment of the healthcare sector'.
Silver stated, 'Perella Weinberg Partners is a highly-respected independent advisory firm, with a significant commitment and track record in healthcare investment banking. I am excited to join their experienced team to further expand coverage of the biopharmaceutical and pharmaceutical services sectors. Commercial and regulatory changes in the healthcare industry are driving high levels of strategic activity and significant evolution of business models. I look forward to working with my new colleagues to help our clients navigate these challenges'.
Perella Weinberg Partners has been actively advising healthcare clients.
Some of the Firm’s recent assignments include advising:
HeartWare International, Inc. in connection with its $149 million common stock offering;
One Lambda in connection with its sale to Thermo Fisher Scientific Inc. for $925 million;
Luminex Corporation in connection with its acquisition of GenturaDx for $50 million;
The Linde Group in connection with its $4.6 billion acquisition of Lincare Holdings Inc.;
Hologic, Inc. in connection with its $3.7 billion acquisition of Gen-Probe Inc.;
Rhön-Klinikum AG in connection with the voluntary public takeover offer by Fresenius SE & Co. KGaA valued at €3.9 billion; and
Caliper Life Sciences, Inc. in connection with its sale to PerkinElmer, Inc. for $640 million.
Biography of Brian Silver
Silver is a Partner at Perella Weinberg Partners. Most recently, he was a Managing Director in Morgan Stanley’s Healthcare Investment Banking Group, where he advised a broad range of biopharmaceutical and pharmaceutical services clients on mergers and acquisitions, initial public offerings, the equity and debt capital markets, and royalty financing.
Prior to joining Morgan Stanley in 1998, Silver was an M&A Associate at Sullivan & Cromwell and an M&A investment banker at Salomon Brothers.
Silver received an A.B. with honors in Social Studies from Harvard College and a J.D. with honors from the University of Chicago Law School.